International Investment Afternoon (London)

A showcase of international investment opportunities in conjunction with our partners at International Deal Gateway.

Speakers

Dr. James Helliwell, MD | Eupraxia Pharmaceuticals

Dr. Helliwell is the Co-founder and CEO of Eupraxia Pharmaceuticals. A board-certified Cardiac Anesthesiologist, he previously maintained a busy quaternary clinical and academic practice with a focus on cardiac transplantation and held a double tenure as President of the Anesthesiologists of BC.

Dr. Helliwell’s experience in the operating room and ICU instilled an appreciation for the value of precision drug delivery to achieve successful patient outcomes. This led him to create Eupraxia Pharmaceuticals, a company developing precision medicines in areas of high unmet medical need. In 2021, Eupraxia became the first biotech to successfully list exclusively on the Toronto Stock Exchange in almost 20 years. The company’s lead product candidate – a long-acting corticosteroid to treat osteoarthritis pain – is currently in Phase 2 clinical development.

Dr. Helliwell has also applied precision delivery to the medical device space. As Co-founder and CEO of Accuro Technologies, he invented Arthrotap® – a medical device to improve the accuracy of intra-articular injections. After successfully transacting on Accuro, he moved on to serve as Chair of the Board for Guidestar Medical Devices – a company focused on precision medicines delivery for the epidural space.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

Eupraxia's lead product candidate, EP-104, is currently in Phase 2 development for the treatment of pain due to osteoarthritis of the knee. The EP-104 platform has expanded into gastrointestinal disease with the launch of a Phase 1b/2a program to treat eosinophilic esophagitis. For further information please visit: www.eupraxiapharma.com.


Jordan Trimble | Skyharbour Resources Ltd.

Jordan Trimble is the President and Chief Executive Officer as well as a Director of Skyharbour Resources Ltd. By background, he is an entrepreneur and has worked in the resource industry in various roles with numerous companies specializing in management, corporate finance and strategy, shareholder communications, business development and capital raising. 

Previous to Skyharbour, he was the Corporate Development Manager for Bayfield Ventures, a gold company with projects in Ontario which was successfully acquired by New Gold (TSX: NGD) in 2014. Bayfield made a high grade gold and silver discovery at its Burns Block property in the Rainy River district which is now a part of the producing Rainy River Mine. Through his career Mr. Trimble has founded and helped manage several public and private companies and has been instrumental in raising substantial amounts of capital for mining companies with his extensive network of institutional and retail investors. He is a frequent speaker at resource and mining conferences globally and has appeared on various media outlets including BNN and the Financial Post. Mr. Trimble holds a Bachelor of Science Degree with a Minor in Commerce from the University of British Columbia and he is a CFA® Charterholder currently serving as a Director of the CFA Society Vancouver. 

Skyharbour holds an extensive portfolio of uranium exploration projects in Canada's Athabasca Basin and is well-positioned to benefit from improving uranium market fundamentals with eighteen projects covering over 460,000 hectares of mineral claims. Skyharbour's goal is to maximize shareholder value through new mineral discoveries, committed long-term partnerships, and the advancement of exploration projects in geopolitically favourable jurisdictions.
 
Investment Highlight: Strong management and technical team with track record of success; timing and an impending turnaround in the uranium market; top tier Athabasca Basin uranium project portfolio with robust discovery potential; Acquiring assets at attractive valuations and using prospect generator and JV model to advance non-core assets; Noteworthy shareholder base and significant insider ownership.

Francis Bellido | Quantum eMotion Corp.

Dr. Bellido has over 35 years of international experience in Cybersecurity, Healthcare and Financial industries and was appointed CEO of Quantum eMotion Corp., (QNC.V) in January of 2020. He was CEO of SoundBite Medical from 2018 to 2020, and CFO from 2015 to 2018.

He managed a $300M life science investment Fund (SGF-Santé) producing major winners: Cryocath, IDI-GeneOhm, Draxis, Medicago, Atrium, Axcan Pharma. Dr. Bellido has served as Board member and Director in more than twenty private and public companies, including at the present time Diagnos (ADK.V), Magneceuticals (USA), RegenLab (CH). He is a former member of the board of DSM Biologics Company Inc., one of the world’s leading biopharmaceutical CMOs.

The Company’s mission is to address the growing demand for affordable hardware security for connected devices. The patented solution for a Quantum Random Number Generator exploits the built-in unpredictability of quantum mechanics and promises to provide enhanced security for protecting high value assets and critical systems.

The Company intends to target the highly valued Financial Services, Healthcare, Blockchain Applications, Cloud-Based IT Security Infrastructure, Classified Government Networks and Communication Systems, Secure Device Keying (IOT, Automotive, Consumer Electronics) and Quantum Cryptography.

John Livingston | Skyfish

John Livingston has served as Skyfish’s Executive Chairman since cofounding the company with Orest Pilskalns in 2014. John brings more than 30 years’ experience both leading and advising software companies. He served as CEO of www.absolute.com for 20 years and grew the company to a $1B market cap. In 2013, John began angel investing and mentoring technology startups and their founders. John is involved in Skyfish’s day-to-day operations, marketing, sales, and hiring. 

Skyfish delivers a drone and visual data platform with advanced inspection and measurement software that improves Infrastructure management and lowers customer operating costs. The Skyfish drone platform enables precision measurement, inspection, and analysis  of critical infrastructure assets. The platform integrates and supports a variety of sensors to  capture the extremely high-quality data necessary to produce engineering-grade 3D reality models or “digital twins”. After 7 years of technology platform development, Skyfish officially launched from stealth mode in 2021 and in 2022 began to sell its fully released drone platform and services.

Vahid Shababi | Hydreight Technologies Inc

Vahid has been the Chief Growth officer for Victory Square technologies and has been working closely with Hydreight team and CEO for the past 18 months to help with their growth and scaling business. He has also been an advisor to FansUnite, GameOn and many other fast-growing startups. He earned a BSC in Electrical and Electronics Engineering from Simon Fraser University in 2008.

Hydreight Technologies Inc. (TSXV: NURS) is a telehealth platform and medical network enabling flexible home healthcare that bridges the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals to deliver services independently, on their own terms, or add mobile services to existing location-based operations. The network offers medical director oversight, liability insurance, HIPAA-compliant documentation, competitively priced prescriptions via a 503B licensed pharmacy, and more. The platform includes a built-in, easy-to-use suite of fully-integrated tools for accounting, documentation, sales, inventory, booking, managing patient data, and more, making it possible to deliver fully-compliant mobile medicine across 50 states.

Stuart Jara, Bob Wowk | HydroGraph Clean Power Inc.

Stuart Jara is a growth driven leader with more than 20 years’ operating experience as an executive, including CEO roles, in industrial, specialty chemicals, clean technology, and hydrogen fuel sectors. 10 years’ experience as operating partner and CEO of PE portfolio companies and startups. Held P&L responsibility for $1.2B business and involved in over $2B of capital investment and acquisitions across 12 countries. He holds an MBA from the University of Michigan Ross School of Business, and a BS in Mechanical Engineering and a BA in International Relations from Lehigh University.  

Bob Wowk has more than 30 years of global finance, strategy, and business development experience in senior finance/CFO roles with Linde, Guld Cryo (Dubai), Fluence, EnergyX, sPower/AES, Plasco and Transform Materials. Multiple successful startup company experience in the renewable sector including solar, waste to energy, lithium extraction, hydrogen. M.B.A. in finance from Wharton and a civil engineering degree from Lafayette College.

HydroGraph is one of the world’s purest producers of graphene, currently positioned to be a global leader in commercializing graphene at scale. Only Graphene council verified producer in US.
HydroGraph’s patented technology uniquely positions the company for multiple high growth markets in the production of graphene, and other strategic materials. 
Patented operating commercial scale  Hyperion System:

• Produces the purest, blackest graphene with the lowest environmental footprint;
• Solves industrial graphene supply problems of value, quality and scale, in nano-material production;
• Most cost-effective producer of high purity graphene in the industry;